Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab DDI Study in Atopic Dermatitis
NCT04562116Phase 2Completed
- Sponsor
- Galderma
- Start
- Dec 2021
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of nemolizumab in atopic dermatitis (AD), sponsored by Galderma. Started Dec 2021; status: completed.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04562116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04562116.